spread of tumors, leading to improved survival of the recipient animal. Nevertheless, the downstream molecular mechanisms underlying CHRM1 signaling in prostate cancer metastasis have not yet been explored. Thus, the function and underlying mechanisms of the CHRM1 in prostate cancer, especially in prostate cancer metastasis, remain to be elucidated.
Hedgehog (Hh) signaling primarily involves sonic hedgehog (SHH), patched 1 (PTCH1), smoothened (SMO), and GLI family zinc finger 1 (GLI1). 19 Once the SHH ligand binds to the membrane anchoring receptor PTCH1, SMO is relieved from PTCH1-mediated repression, which leads to dissociation of the suppressor of fused (SUFU)-GLI1 complex and translocation of the GLI1 transcription factor. Hh signaling plays a central role in embryonic development, histological differentiation, and organ formation. 20 Moreover, Hh signaling pathway activation contributes to tumor aggressiveness by inducing cell proliferation, stimulating angiogenesis, and inhibiting cell apoptosis. [21] [22] [23] [24] In many prostate cancer tissues, SHH, PTCH1, GLI1, GLI2, and GLI3 are upregulated compared with their levels in matched normal tissues. 21 Pathway activity is closely related to prostate cancer development and invasiveness. 25, 26 Recent studies have reported that SHH promotes perineural invasion (PNI) in pancreatic cancer. 27 Other studies have indicated that Hh signaling cross talks with other signaling pathways, such as transforming growth factor beta (TGF-β) and Notch signaling, 28 suggesting that there is a possible connection between the CHRM1 and Hh signaling. A previous study demonstrated that CHRM1 promotes prostate cancer metastasis. 1 However, it remains unclear whether the CHRM1 and Hh signaling are correlated in prostate cancer invasion.
The aim of this study was to investigate the molecular mechanisms that promote prostate cancer, including changes in the hedgehog signaling pathway and the migration and invasion abilities of prostate cancer cells after treatment with a CHRM1 antagonist or agonist.
MATERIALS AND METHODS

Cell culture and drugs
The human androgen-independent prostate cancer cell line PC-3 was obtained from BeNa Culture Collection (BNCC, Beijing, China). The androgen-dependent prostate cancer cell line LNCaP and the non-small cell lung cancer cell line A549 (this tumor cell line was randomly selected to compare CHRM1 expression between prostate and other derived cancers) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The human normal epithelial prostate cell line RWPE-1 was obtained from China Center for Type Culture Collection (CCTCC, Wuhan, China). PC-3 and LNCaP cells were grown in Dulbecco's modified Eagle's medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Cellmax, Lanzhou, China) and 1% antibiotic mixture (penicillin/streptomycin; Solarbio, Beijing, China). A549 cells were maintained in Roswell Park Memorial Institute (RPMI 1640; Thermo Fisher Scientific) medium supplemented with 10% FBS and 1% antibiotic mixture. RWPE-1 cells were grown in keratinocyte serum-free medium (K-SFM; Gibco, Carlsbad, CA, USA) supplemented with 10% FBS and 1% antibiotic mixture. These four cell lines were cultured at 37°C in a 5% CO 2 and 95% humidified atmosphere. The nonselective muscarinic receptor agonist carbamoylcholine chloride (carbachol; T0105, Targetmol, Shanghai, China), CHRM1-specific antagonist pirenzepine (T1542, Targetmol), and Hh pathway antagonist GANT61 (HY-13901, MCE, Monmouth Junction, NJ, USA) were dissolved in dimethyl sulfoxide (DMSO; Sigma, Milwaukee, WI, USA) and stored at 4°C. The solutions were diluted to the final concentration with culture medium, and treatment with vehicle (DMSO, Sigma) was used for control cells.
Cell proliferation assay P C -3 c e l l s w e r e s e e d e d i n 9 6 -w e l l p l at e s a n d w e r e l e f t u nt re ate d ( c ont rol ) or t re ate d w it h pi re n z e pi n e or carbachol the next day at dif ferent concentrations according to prior studies. 29 Cell proliferation was assessed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) assays after incubation with drugs for 24 h. At the indicated time point, 10 μl of MTT solution was added to each well, and the cells were incubated at 37°C for an additional 4 h. Formazan was dissolved in DMSO, and absorbance was measured at 490 nm using a spectrophotometer (BioTeK, Vinooski, VT, USA). Each concentration was tested in five replicates. The results are expressed as the mean ± standard error of the mean (s.e.m.).
Cell migration and invasion assays
In the migration assays, 20 000-100 000 cells in 100 μl of serum-free medium were seeded on the top of a Transwell chamber (8.0 μm pore size, Corning, Vineland, NJ, USA), and 600 μl of medium containing 20% FBS was added in the bottom of 24-well plates to induce cell migration. In the invasion assays, an additional 60 μl of Matrigel matrix (356234, Corning) was added on the top of the Transwell chamber before seeding cells as described. 30 Cells were left untreated (control) or treated with carbachol (2 μg ml −1 ) or pirenzepine (110 μg ml −1 ) for 24 h. The culture inserts were fixed with 4% paraformaldehyde and then stained with crystal violet (Beyotime, Shanghai, China) for 15 min. Cells that stayed on the top of the membrane were lightly scraped away with a cotton swab. Migrated cells were counted under a high-power microscope (OLYMPUS, Tokyo, Japan) in five random fields.
Western blotting analysis PC-3 cells were seeded in 6-well or 12-well plates and left untreated (control) or treated with carbachol (2 μg ml −1 ) or pirenzepine (110 μg ml −1 ) for 2, 4, 6, 12, and 24 h. Cells were lysed in NP 40 buffer (Solarbio, Beijing, China) containing protease inhibitors. Total protein was measured using the Bicinchoninic acid (BCA) method (Beyotime). Primary antibodies against SHH (1:2000, Abcam, Cambridge, MA, USA), PTCH1 (1:1000, Abcam), GLI1 (1:1000, CST, Beverly, MA, USA), and CHRM1 (1:1000, Abcam) as well as horseradish peroxidase (HRP)-conjugated secondary antibodies (ZSbio, Beijing, China) were applied. Equal protein sample loading was monitored using an anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (1:5000, Ray Antibody, Beijing, China). The probed proteins were visualized with an enhanced chemiluminescence (ECL) blotting detection kit (BIO-RAD, Chengdu, China).
Real-time PCR assays
PC-3 cells were seeded in 6-well plates and left untreated (control) or treated with different concentrations of pirenzepine at 37°C for 24 h. Total RNA was extracted with Trizol reagent (TaKaRa, Kusatsu, Japan) according to the standard protocol. cDNA was synthesized using a Primescript™ RT reagent kit (TaKaRa). Conventional and quantitative real-time PCR assays were performed as described. 10, 31 The oligonucleotide primers are listed in Table 1 . The conditions for RT-PCR amplification were as follows: 95°C for 30 s followed by 39 cycles of 95°C for 5 s, annealing temperature for 30 s, and a final cycle at 65°C for 5 s and 95°C for 15 s. Each sample was run in triplicate. The data were analyzed with the comparative ΔΔC T method, with actin beta (ATCB) gene expression as an endogenous reference.
Immunohistochemical staining
The human prostate cancer tissue array slides (PR633, Alenabio, Xi'an, China) included 60 spots characterized as follows: 34 cases of early-stage prostate cancer, 26 cases of late-stage prostate cancer, 50 cases of non-metastatic prostate cancer, and 10 cases of metastatic prostate cancer. Early-stage prostate cancer included stage I and stage II patients, and late-stage prostate cancers included stage III and stage IV patients. The median age of the patients was 69.5 years old. Case data included pathology diagnosis, Gleason score, stage, and tumor node matastasis (TNM) status. The cultured PC-3, LNCaP, and A549 cells are described above. The three cell lines were not treated with any drugs before staining. A primary antibody against CHRM1 (1:500) and a HRP-conjugated secondary antibody (PV-9000, Zsbio) were applied. The immunohistochemical staining was visualized with 3,3'-diaminobenzidine (DAB; Zsbio). Images of five random fields were captured using a microscope under the same exposure conditions and analyzed with Image-pro Plus 6.0 software (Media Cybernetics, Silver Spring, MD, USA).
Statistical analyses
The data in this study are expressed as the means ± s.e.m. All statistical analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Statistical significance for three or more groups was assessed by ANOVA and Mann-Whitney U test (2-tailed). Two groups were compared with Student's t-test. Significance was set at P < 0.05 ( * P < 0.05, ** P < 0.01, and *** P < 0.001).
RESULTS
CHRM1 expression is upregulated in the early stages of prostate cancer
To confirm CHRM1 expression in human prostate cancers, we conducted immunohistochemical staining of prostate cancer tissue array slides. We observed frequent CHRM1 expression in the prostate cancer tissues (60/60) with different degrees of staining intensities. CHRM1 was mainly expressed in epithelial cells surrounding the prostate gland (Figure 1a-1d) . We analyzed the relationship between CHRM1 expression and clinicopathological features in the prostate cancer samples and found that CHRM1 was remarkably overexpressed in early-stage (stage I and II) prostate cancer compared with its expression level in late-stage (stage III and IV) prostate cancer (P = 0.008; Figure 1e ), whereas there were no significant differences in CHRM1 expression between nonmetastatic and metastatic prostate cancers (Figure 1f) . These results suggest that CHRM1 upregulation might occur in the early stages of prostate cancer.
CHRM1 expression in prostate cancer cells
We compared the expression of CHRM1 in the normal epithelial prostate cell line RWPE-1 and two prostate cancer cell lines (PC-3 and LNCaP) via western blotting analysis. The protein expression level of CHRM1 was much higher in the two prostate cancer cell lines than that in RWPE-1 cell line (Figure 2a) . Furthermore, we made an analysis of the protein expression level of CHRM1 in the two prostate cancer cell lines (PC-3 and LNCaP) and in a non-small cell lung cancer cell line A549. The results showed that the expression of CHRM1 in PC-3 and LNCaP cells was approximately 65% more than that in A549 cells at protein level (Figure 2b) . Cell immunohistochemical staining showed that CHRM1 was localized in cell membranes and cytoplasm (Figure 2c-2e) . These results suggest that substantial CHRM1 is expressed in PC-3 and LNCaP prostate cancer cell lines.
CHRM1 activation promotes prostate cancer cell migration and invasion
To determine an optimal drug concentration for use in this study, experiments on PC-3 cells were conducted with CHRM1-specific antagonist pirenzepine and nonselective muscarinic receptor agonist carbachol. Pirenzepine inhibited the PC-3 cell proliferation at 100-140 μg ml −1 in a concentration-dependent manner (Figure 2f) . In contrast, carbachol promoted PC-3 cell proliferation at concentration of 2-10 μg ml −1 even though these changes did not reach statistical significance (Figure 2g) . Thus, we used 110 μg ml −1 pirenzepine and 2 μg ml −1 carbachol in subsequent studies. To investigate the role of CHRM1 in regulating cell migration and invasion, cell migration and invasion assays were performed. Carbachol (2 μg ml −1 ) dramatically stimulated the invasion of PC-3 and LNCaP cell lines, while pirenzepine (110 μg ml −1 ) markedly inhibited the invasion of all three cell lines (P = 0.006; Figure 3a and 3b) . Similarly, carbachol promoted the migration of LNCaP and A549 cell lines, and pirenzepine significantly inhibited the migration of PC-3 and A549 cell lines (P = 0.014; Figure 3c and 3d) . Thus, these data suggest that CHRM1 activation promotes prostate cancer cell migration and invasion and has a similar effect on lung cancer cells expressing CHRM1.
CHRM1 stimulation promotes hedgehog signaling activation
Western blotting was applied to detect protein expression levels of GLI1, PTCH1, and SHH. GLI1 and PTCH1 protein levels were increased in a time-dependent manner after exposure to carbachol (Figure 4a and 4b) . In addition, the expression of GLI1 and PTCH1 was prevented by pirenzepine, a CHRM1-specific antagonist (Figure 4c and 4d) , while the expression of SHH was scarcely affected by carbachol or pirenzepine (Figure 4a-4d) . Furthermore, we measured the mRNA abundance of GLI1, PTCH1, and SHH in PC-3 cells treated with multiple concentrations of pirenzepine. GLI1 mRNA expression was clearly inhibited by pirenzepine at all the applied concentrations (P = 0.037; Figure 4e) . Although PTCH1 mRNA level was slightly increased after treatment with pirenzepine in PC-3 cells, it did not reach statistical significance (Figure 4f) . In addition, the SHH mRNA expression level was scarcely affected by 9,10 Substantial CHRM1 expression was observed in human prostate adenoma and in the PC-3 and LNCaP prostate cancer cell lines, indicating a potential role of CHRM1 in prostate cancer progression. Surprisingly, the expression of CHRM1 was higher in early stages of human prostate adenoma than in late stages. This phenomenon may have been due to the low sample number (n = 60) in our study or to the greater number of early-stage cases (n = 34) than late-stage cases (n = 26). We analyzed the relationship between CHRM1 immune reactivity and Gleason score (Gleason 3 + 3, Gleason 3 + 4, Gleason 4 + 3, and Gleason 8-10). There was no significant difference in CHRM1 expression between different Gleason score groups (data not shown), similar to the results in nonmetastatic and metastatic groups. It has been reported that CHRM1 mRNA expression is associated with prostate size, but not associated with age, prostate-specific antigen level (PSA), and pathological diagnosis (BPH vs prostate cancer). 10 Hence, our study may not take into account some potential-affecting factors. CHRM1 overexpression in early stages of human prostate cancer may partly explain why denervation should be performed in early stages of tumors and why later denervation does not prevent cancer pirenzepine (Figure 4g) . Together, these data support the concept that CHRM1 stimulation promotes Hh signaling activation mainly by regulating GLI1 and PTCH1.
Hedgehog signaling inhibition attenuates carbachol-induced prostate cancer cell migration
To further investigate whether carbachol affects prostate cancer cell migration through Hh signaling, we examined the effect of Hh signaling blockade on carbachol-induced cell migration. Compared with that in the control group, the migratory ability of PC-3 cells was inhibited after treatment with 3 μmol l -1 GANT61 (Figure 5a and 5b), which is a GLI inhibitor by suppressing the DNA-binding capacity of GLI. 32 As expected, the migratory ability of PC-3 cells was stimulated by treatment with 10 μmol l -1 carbachol (Figure 5a and 5c) . The inhibitory effect of GANT61 on muscarinic signaling is shown in Figure 5d . GANT61 counteracted the carbachol-stimulated migration of PC-3 cells (Figure 5c-5e) . These results indicate that Hh signaling blockade attenuates carbachol-induced migration in PC-3 prostate cancer cells.
DISCUSSION
The role of the autonomic nervous system in tumorigenesis and progression has received increasing attention in recent years. PNI, a process defined as cancer cell invasion along nerves, is a characteristic phenomenon in certain epithelial malignancies, including prostate and pancreatic carcinomas. 33, 34 This distinct pathological entity has been reported in approximately 75% of prostatectomy specimens and has been suggested to be correlated with poor prognosis. 35, 36 With regard to the parasympathetic branch of the nervous system, the integrated, functional loop comprises nerve bundles, acetylcholine, and corresponding receptors, and all of these have been associated with prostate cancer growth and progression. Our work focused on development and metastasis. 18 In light of the important role of type 1 muscarinic receptor in mouse prostate cancer metastasis, the role of type 1 muscarinic receptor in human prostate cancer deserves more investigation. Previous studies have showed that pirenzepine exerts an antiproliferative effect at dose of 100-125 μg ml −1 and carbachol promotes cell proliferation at 10 μmol l −1 in PC-3 cells. 29 We observed similar effect induced by pirenzepine and carbachol in PC-3 cells, though the effect of carbachol did not reach statistical significance. In PC-3luc tumor-bearing mice, carbachol treatment enhances tumor cell invasion lymph nodes, and pirenzepine inhibits lymph node invasion.
1 CHRM1 activation may also promote migration and invasion of prostate cancer cell lines. Activation of CHRM1 by carbachol promoted the migration and invasion of PC-3 and LNCaP prostate cancer cells and A549 lung cancer cells expressing CHRM1, while suppression of CHRM1 by pirenzepine inhibited the migration and invasion of PC-3, LNCaP, and A549 cells. Thus, our results strongly suggest a pivotal role for CHRM1 in regulating prostate cancer cell migration and invasion. However, the role of muscarinic receptors in cancer progression has been debated due to controversial research results. A recent study has suggested that the CHRM3 contributes to human colon cancer cell migration and invasion. 37 In addition to neuronal cholinergic signaling, a more recent study has reported that autocrine acetylcholine and CHRM3 promote prostate cancer growth and castration-resistant prostate cancer (CRPC). 38 Therefore, it remains unclear whether CHRM1, CHRM3, or the synergistic effect of CHRM1 and CHRM3 plays a major role in prostate cancer progression. Considering that CHRM1 and CHRM3 are both expressed in prostate tissues, single or co-knockout of CHRM1 and CHRM3 is likely a good approach to distinguish the different role of CHRM1 and CHRM3 in prostate cancer progression.
Moreover, previous studies have revealed that Hh signaling promotes the development and dissemination of multiple tumors, including prostate cancer, 25, 27 and that it also participates in the growth and maintenance of neurons in normal and tumor tissues. [39] [40] [41] On the basis of the possible consistency between nerves and CHRM1, we investigated the relationship between Hh signaling and CHRM1 in PC-3 prostate cancer cells treated with carbachol or pirenzepine. Western blotting results showed that GLI1 and PTCH1 levels markedly increased in PC-3 cells after exposure to carbachol. In contrast, the expression of GLI1 and PTCH1 was prevented by pirenzepine, a CHRM1-specific antagonist. However, the expression of SHH was scarcely affected by carbachol or pirenzepine. RT-PCR analysis confirmed similar results, except for the expression of PTCH1, which was slightly increased in PC-3 cells treated with pirenzepine (P > 0.05). This result may be due to transcriptional regulation of Hh signaling, because PTCH1 is a negative target gene of Hh signaling. 42 Moreover, the carbachol-induced migration of PC-3 cells was counteracted by GANT61, an antagonist of Hh signaling. Collectively, our data suggest that CHRM1 promote prostate cancer migration and invasion through Hh signaling-mediated activation of GLI1 and PTCH1 in PC-3 cells. However, it remains unclear how CHRM1 impacts Hh signaling. Studies have demonstrated that certain GPCRs regulate Hh signaling. For example, Gs-coupled Gpr161 is a negative regulator of Hh signaling by mediating cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling. 43 Gpr161 increases cellular cAMP/PKA levels, increases PKA-phosphorylated GLI3, and ultimately downregulates Hh signaling. In contrast, Gi-coupled Gpr175 enhances Hh signaling by downregulating cAMP levels. 44 Another report has suggested that phosphoinositide 3-kinase (PI3K) and AKT signaling are essential for Hh signaling.
45
CHRM1 is a GPCR linked with Gq-type G proteins, which initiate PI metabolism and AKT phosphorylation. Thus, we hypothesized that CHRM1 affects Hh signaling (Figure 5f ). Activation of Gq-coupled CHRM1 promotes AKT phosphorylation, thereby stabilizing the activation of GLI (GLI-A). AKT may also antagonize PKA-mediated repression of GLI (GLI-R), 45 consequently activating Hh signaling. This hypothesis is important and should be further studied.
In summary, the present study results suggest that CHRM1 is involved in regulating prostate cancer migration and invasion through hedgehog signaling pathway activation. CHRM1-specific antagonist pirenzepine inhibit the dissemination of PC-3 and LNCaP prostate cancer cells and A549 lung cancer cells. Muscarinic receptor antagonists have a wide variety of clinical applications, such as for the treatment of gastric ulcer (GU), chronic obstructive pulmonary disease (COPD), and schizophrenia; 5 clinical strategies such as CHRM1 antagonists and Hh signaling inhibitors may be potential therapeutic options for prostate cancer treatment.
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